Keryx Biopharma (KERX) Posts Q4 Loss of 44c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Roth Capital Trims PT on Keryx Biopharma (KERX) to $27; 'Blocking and Tacking' w/ Medicare to Ensure Auryxia Success
February 27, 2015 10:36 AM ESTRoth Capital affirms Keryx Biopharma (Nasdaq: KERX) at Buy and lowers its price target from $32 to $27 following Q4/FY14 results issued earlier Friday.
Analyst Joseph Pantginis noted that Keryx's FY14 loss of $1.23 per share compared with the firm's loss estimate of $1.18 per share. No revenue was reported for Auryxia,... More
Keryx Biopharma (KERX) Announces Departure of CFO Oliviero
February 27, 2015 7:49 AM ESTOn February 27, 2015, Keryx Biopharma (NASDAQ: KERX) announced a planned consolidation of its finance and accounting function into its Boston office and that its Chief Financial Officer, James Oliviero, will be leaving Keryx by October 2015. Mr. Oliviero has been with Keryx for twelve... More
